2-Guanidino-quinazoline promotes the readthrough of nonsense mutations underlying human genetic diseases

Area of Science:

• Genetics
• Pharmacology
• Molecular Biology

Background:

• Premature termination codons (PTCs) cause 10-20% of human genetic disorders by leading to non-functional proteins.
• Drug-induced PTC readthrough can restore full-length protein production, presenting a therapeutic avenue.
• A wider range of readthrough-inducing compounds is needed for broader clinical use.

Purpose of the Study:

• To develop a reporter cell line and conduct high-throughput screening (HTS) to identify novel PTC readthrough inducers.
• To evaluate the therapeutic potential of the identified compound, TLN468, for Duchenne muscular dystrophy (DMD)-associated PTCs.

Main Methods:

• Developed a reporter cell line for high-throughput screening (HTS).
• Screened for compounds that promote PTC readthrough.
• Assessed the efficacy of the lead compound, TLN468, on 40 common DMD-associated PTCs.
• Compared TLN468's performance against gentamicin and evaluated its specificity for PTCs versus normal stop codons.

Main Results:

• Identified 2-guanidino-quinazoline (TLN468) as a potent readthrough inducer through HTS.
• TLN468 demonstrated higher efficiency than gentamicin in promoting readthrough for DMD-associated PTCs.
• TLN468 exhibited activity across a broader range of PTC sequences.
• Crucially, TLN468 did not induce readthrough of normal stop codons (TC), indicating specificity.

Conclusions:

• TLN468 is a highly effective and specific PTC readthrough inducer.
• This compound holds significant therapeutic potential for genetic diseases caused by PTCs, particularly DMD.
• TLN468 represents a valuable addition to the chemical arsenal for PTC readthrough therapies.